Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

22.65 -0.15 (-0.66%)
Streaming Delayed Price Updated: 3:43 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)
Students from The University of Notre Dame Selected to Participate in a Week-long Biopharmaceutical Learning Intensive 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What's Behind the Move? ↗
The exercise-and-sell transaction came as the rare disease drugmaker reported strong quarterly results. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top GARP Stock Pick ↗
Catalyst Pharmaceuticals (CPRX) exemplifies the GARP strategy with strong growth, high profitability, and a reasonable valuation in the biotech sector. 
Via Chartmill
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Growth Stock with a Bullish Technical Setup ↗
Catalyst Pharmaceuticals (CPRX) combines strong growth fundamentals with a bullish technical setup, offering a rare biotech investment opportunity. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Passes the Caviar Cruise Quality Investing Screen ↗
Catalyst Pharmaceuticals exemplifies quality investing with high growth, exceptional profitability, a debt-free balance sheet, and an attractive valuation. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Represents an Affordable Growth Opportunity ↗
Catalyst Pharmaceuticals offers strong growth, solid profitability, and a debt-free balance sheet, all at an attractive valuation compared to its biotech peers. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Combines Strong Growth with Bullish Technical Setup ↗
Discover Catalyst Pharmaceuticals (CPRX), a growth stock with strong earnings and a bullish technical breakout pattern, signaling potential upside. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™
Attributes 249% Revenue Growth to Portfolio Momentum and Focused Execution 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Stands Out as a Quality Investment on Caviar Cruise Screen ↗
Catalyst Pharmaceuticals is a high-quality growth stock with exceptional profitability, zero debt, and strong cash flow, making it a standout in the biotech sector. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Shows Strong Fundamentals and Technical Breakout Potential ↗
Discover Catalyst Pharmaceuticals (CPRX), a biopharma stock with strong EPS growth, high profitability, and a bullish technical breakout pattern. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Presents a Compelling Case for Affordable Growth ↗
Discover Catalyst Pharmaceuticals (CPRX), a biopharma stock with strong growth, solid earnings, and an affordable valuation for investors seeking value. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025
The Company will Host a Conference Call and Webcast on Thursday, November 6, 2025, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
What Does the Market Think About Catalyst Pharmaceuticals Inc? ↗
 
Via Benzinga
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Value Investment with Strong Fundamentals ↗
Catalyst Pharmaceuticals (CPRX) appears undervalued with strong financials: zero debt, high profitability, and robust growth, making it a compelling value investing candidate. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Presents a Compelling Case for Affordable Growth ↗
Discover Catalyst Pharmaceuticals (CPRX): a high-growth biotech stock with strong profitability, a solid balance sheet, and an attractive valuation. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Value Investing Opportunity with Strong Fundamentals ↗
Catalyst Pharmaceuticals (CPRX) is a value investing candidate with strong fundamentals, low P/E ratios, robust financial health, high profitability, and impressive growth in the rare disease sector. 
Via Chartmill
News headline image
How Is The Market Feeling About Catalyst Pharmaceuticals? ↗
 
Via Benzinga
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top GARP Investment with Strong Growth and Reasonable Valuation ↗
Catalyst Pharmaceuticals (CPRX) is a top GARP stock with strong growth, excellent profitability, and an attractive valuation, making it a compelling long-term investment. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Stands Out as a High-Quality Caviar Cruise Candidate ↗
Catalyst Pharmaceuticals (CPRX) excels in growth, profitability, and financial health, making it a top-quality stock for long-term investors according to the Caviar Cruise screen. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.